China Pharma Holdings, Inc. — Q1 2021 Form 10-Q
Business and period: Unaudited results for the three months ended March 31, 2021, compared with Q1 2020. The company develops, manufactures, and sells pharmaceutical products in China; substantially all operations and revenue are in the PRC.
Key financial results
| Metric | Q1 2021 | Q1 2020 | Change / context |
|---|---|---|---|
| Revenue | $2.36 million | $1.76 million | Up 33.7% |
| Gross profit / margin | $273,000 / 11.6% | $194,000 / 11.0% | Margin improved 0.6 percentage points |
| Operating loss | $696,000 | $599,000 | Loss increased |
| Net loss | $767,000 | $661,000 | Loss increased; basic and diluted loss per share was $0.02 in both periods |
| Operating cash flow | $(277,000) | $(244,000) | Cash used increased |
| Cash and cash equivalents | $535,000 | $958,000 at Dec. 31, 2020 | Down about 44%; cash is held in China and not expected to be available to the parent |
| Total assets / liabilities | $19.85 million / $12.68 million | $21.12 million / $13.11 million at Dec. 31, 2020 | Current assets $4.88 million versus current liabilities $11.03 million |
Scheduled 2021 principal payments on the construction loan and lines of credit totaled approximately $4.15 million; an additional $852,000 of line-of-credit principal was scheduled for 2022. Related-party borrowings were $2.18 million. The filing reports total stockholders’ equity of $7.17 million.
Changes and management commentary
- Revenue recovery was attributed mainly to improved business conditions after COVID-19 disruptions in early 2020 and exchange-rate effects. Anti-viral/infection and respiratory products generated 56% of revenue; CNS/cerebral and cardiovascular products generated 22%.
- Gross margin edged up, but operating and net losses widened. Management attributed the higher net loss mainly to R&D expense, which increased to $190,000 from $49,000, largely for generic-drug consistency evaluations.
- Management said it is pursuing a product consistency-evaluation submission after a product passed bioequivalence testing in March 2021. It also cited plans to strengthen advance-payment sales and receivables collection, and to explore strategic alternatives to accelerate nutrition-product launches. No quantified financial guidance was provided.
- China’s centralized drug procurement can substantially reduce prices, while consistency evaluations affect eligibility. Management described uncertainty over policy details, investment, and returns; these factors may affect product economics and launch decisions.
Liquidity, risks, and unusual items
- Going concern: The filing states that recurring losses, limited cash, and debt-service needs raise substantial doubt about the company’s ability to continue as a going concern within one year after issuance. Management’s plans were not sufficiently finalized or within its control to alleviate that doubt under the applicable assessment. The CEO/chair advanced a net amount of approximately $829,000 by March 31 for working capital; continued support is not assured.
- Receivables: Net trade receivables were $545,000, against an allowance for doubtful accounts of $18.0 million. The filing’s aging table says 96.74% of receivables were over 720 days old. Collection and allowance assumptions are important to monitor.
- Debt and refinancing: Construction-loan principal of about $2.13 million was current at March 31, with repayment due July 2021. The company also had short-term bank lines and related-party funding; CEO guarantees and pledged personal assets support certain facilities. Availability of further financing is uncertain.
- Other risks: COVID-19 could again disrupt suppliers, customers, distribution, or operations. Revenue is denominated in RMB, and PRC foreign-currency conversion and remittance controls may restrict transfers to the parent. Two suppliers represented 45.1% and 20.1% of raw-material purchases.
- Tax: Approximately $19.8 million of PRC tax-loss carryforwards were due to expire in December 2021; the company reported a valuation allowance against deferred tax assets.
- Controls: Management concluded disclosure controls were ineffective at March 31 because of a material weakness involving insufficient personnel knowledgeable in U.S. GAAP financial reporting. Management nevertheless stated the statements were fairly presented in all material respects.
Important facts for investors to verify
- Share-count inconsistency: the balance sheet reports 45,579,557 shares at March 31, while the cover page reports 43,579,557 shares outstanding as of May 14, 2021.
- Near-term debt maturities, repayment or refinancing plans, and whether the CEO will continue providing working-capital support.
- Receivables aging, actual collections, and the adequacy of the large doubtful-account allowance.
- Progress and expected costs or commercial returns from consistency evaluations, centralized procurement exposure, and nutrition-product plans.
- Remediation of the material weakness and the company’s ability to fund operations despite the stated going-concern doubt.